---

---

symbols : Azn   

save search

---

Fortress Biotech to Participate in Three March 2022 Investor Conferences
Published: 2022-03-09 (Crawled : 23:00) - globenewswire.com
AZNCF | $138.24 800 |

Health Technology

| 19.92% | O: 0.32% H: 7.71% C: 5.4%
FBIO | $1.765 -2.49% 90K |

Health Technology

| 33.33% | O: 1.52% H: 8.21% C: 8.21%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 19.97% | O: 3.16% H: 3.23% C: 2.95%
conference biotech iot

---

HUTCHMED Reports 2021 Interim Results and Provides Business Updates
Published: 2021-07-28 (Crawled : 12:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 208.22% | O: -0.09% H: 2.07% C: 1.29%
HCM | $16.41 0.31% 12K |

Health Technology

| -54.87% | O: 6.45% H: 7.99% C: 7.76%
BGNE | $130.63 -1.01% 69K |

Health Technology

| -50.21% | O: 3.23% H: 13.33% C: 12.51%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 18.8% | O: -0.75% H: 0.7% C: -0.39%
results

---

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio
Published: 2024-01-26 (Crawled : 02:00) - prnewswire.com
XLO | $1.24 -3.13% 28K |

Professional, Scientific, and T...

| 100.0% | O: 4.69% H: 4.55% C: -2.99%
AZNCF | $138.24 800 |

Health Technology

| 2.47% | O: 2.92% H: 1.06% C: -3.05%
BNTX | $87.02 0.99% 140K |

Health Technology

| -11.07% | O: -1.35% H: 0.12% C: -0.83%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 1.86% | O: 1.07% H: 0.1% C: -0.94%
AGEN | $5.62 13.08% 510K |

Health Technology

| 728.61% | O: 3.13% H: 11.02% C: 7.11%
protein growth market

---

Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| 29.9% | O: -0.06% H: 0.0% C: 0.0%
AZNCF | $138.24 800 |

Health Technology

| 12.29% | O: 6.22% H: 3.13% C: -0.56%
NVS | $93.815 1.35% 410K |

Health Technology

| 12.19% | O: 2.81% H: 0.43% C: -0.2%
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| -16.77% | O: 0.18% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| 22.15% | O: 2.59% H: 0.72% C: 0.63%
BMY | $48.56 0.54% 1.8M |

Health Technology

| -39.46% | O: 1.22% H: 0.01% C: -1.7%
IOVA M | $11.33 -3.33% 1.4M |

Health Technology

| 50.51% | O: 6.12% H: 4.99% C: 4.21%
INO 3 d | $9.755 -4.36% 110K |

Health Technology

| 367.89% | O: 5.5% H: 4.35% C: 3.48%
GILD | News | $66.495 0.51% 1.9M |

Health Technology

| -18.73% | O: 1.43% H: 0.36% C: -1.08%
ATRA | $0.6944 0.39% 350K |

Health Technology

| -82.43% | O: 2.58% H: 23.12% C: 20.85%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 11.82% | O: 7.08% H: 0.84% C: -0.43%
ADAP | $1.04 15.76% 700K |

Health Technology

| -50.95% | O: 0.0% H: 7.14% C: 5.71%
covid-19 research global immunotherapy report impact technology market

---

F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-12 (Crawled : 12:15) - globenewswire.com
FSTX | $7.12 0.0% 0 |

Health Technology

| 7.64% | O: -3.93% H: 13.46% C: 5.67%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 20.59% | O: 0.79% H: 0.84% C: 0.7%
financial results results

---

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
Published: 2021-09-20 (Crawled : 01:00) - globenewswire.com
HCM | $16.41 0.31% 12K |

Health Technology

| -56.77% | O: 1.1% H: 0.0% C: 0.0%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 21.53% | O: 0.0% H: 4.33% C: 4.15%
endocrine

---

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMajor achievements in 2023 lay the foundation for key upcoming milestones
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
AZNCF | $138.24 800 |

Health Technology

| 2.22% | O: 0.75% H: 0.04% C: -0.1%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 3.03% | O: -0.08% H: 0.33% C: -0.53%
ARTL | $1.28 1.8K |

Health Technology

| -4.61% | O: -4.61% H: 4.83% C: 3.84%
business lay key financial results foundation

---

USD 8 Bn growth opportunity in HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market | North America to emerge as key market | Technavio
Published: 2022-05-25 (Crawled : 04:00) - prnewswire.com
AZNCF | $138.24 800 |

Health Technology

| 2.15% | O: -1.42% H: 2.73% C: 2.73%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 24.44% | O: 0.89% H: 0.0% C: 0.0%
VTRS | $11.2 0.72% 1M |

Health Technology

| -3.56% | O: -0.26% H: 3.13% C: 2.96%
NVS | $93.815 1.35% 410K |

Health Technology

| 2.15% | O: 0.29% H: 0.0% C: 0.0%
PBYI | $4.985 -0.1% 71K |

Health Technology

| 176.47% | O: -1.6% H: 6.52% C: 3.8%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 2.27% | O: -0.45% H: 0.89% C: 0.54%
AMGN | $265.32 0.98% 550K |

Health Technology

| 6.21% | O: 1.42% H: 0.72% C: 0.0%
america growth market her2- her2

---

Blueprint Medicines Reports First Quarter 2022 Results
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
BPMC | News | $87.16 -1.96% 130K |

Health Technology

| 49.64% | O: 3.73% H: 5.92% C: 3.09%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 3.17% | O: 0.48% H: 1.18% C: 1.02%
results

---

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2022-08-12 (Crawled : 08:00) - biospace.com/
AZN | $68.545 0.27% 1.2M |

Health Technology

| 5.59% | O: 0.09% H: 3.83% C: 2.98%
enhertu lung approved therapy cancer her2- her2

---

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Published: 2022-08-12 (Crawled : 12:00) - biospace.com/
AZN | $68.545 0.27% 1.2M |

Health Technology

| 5.59% | O: 0.09% H: 3.83% C: 2.98%
enhertu lung approved therapy cancer her2- her2

---

Notice of annual general meeting of H+H International A/S
Published: 2022-03-09 (Crawled : 11:00) - globenewswire.com
AZNCF | $138.24 800 |

Health Technology

| 19.92% | O: 0.32% H: 7.71% C: 5.4%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 19.97% | O: 3.16% H: 3.23% C: 2.95%

---

Vascular Endothelial Growth Factor (VGEF) Inhibitors Market: 36% Market Growth to Originate from North America | Technavio
Published: 2022-05-17 (Crawled : 06:00) - prnewswire.com
AZNCF | $138.24 800 |

Health Technology

| 6.89% | O: 4.22% H: 0.0% C: -2.05%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 29.87% | O: 0.55% H: 0.0% C: 0.0%
VTRS | $11.2 0.72% 1M |

Health Technology

| 0.18% | O: 0.54% H: 3.32% C: 2.78%
NVS | $93.815 1.35% 410K |

Health Technology

| 7.35% | O: 1.63% H: 0.0% C: 0.0%
BHC | $8.655 0.64% 750K |

Health Technology

| -18.7% | O: 2.79% H: 0.0% C: 0.0%
ABBV | News | $164.91 0.15% 1.2M |

Health Technology

| 7.01% | O: 0.46% H: 0.0% C: 0.0%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -12.51% | O: 1.5% H: 0.64% C: 0.19%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 7.55% | O: 3.17% H: 0.0% C: 0.0%
AMGN | $265.32 0.98% 550K |

Health Technology

| 9.56% | O: 0.99% H: 0.0% C: 0.0%
america growth market

---

Breakthroughs In Treating Killer Diseases Could Lengthen Life
Published: 2022-06-07 (Crawled : 15:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| -26.55% | O: 0.0% H: 0.86% C: 0.84%
AZNCF | $138.24 800 |

Health Technology

| 7.73% | O: 4.83% H: 0.0% C: -5.0%
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| -18.22% | O: -0.18% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -7.5% | O: 0.37% H: 3.03% C: 2.98%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 138.6% | O: -3.62% H: 0.0% C: 0.0%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 7.47% | O: 0.54% H: 2.78% C: 2.69%
life disease

---

Global Opioid Induced Constipation Drugs Market Report to 2030 - by Drug Type, Prescription Type and Region
Published: 2022-09-28 (Crawled : 15:00) - prnewswire.com
AZNCF | $138.24 800 |

Health Technology

| 27.05% | O: 2.35% H: 0.0% C: -0.68%
PFE A | $25.615 0.89% 9.9M |

Health Technology

| -42.35% | O: 1.32% H: 0.31% C: -0.54%
IRWD | $7.735 1.78% 480K |

Health Technology

| -26.0% | O: 1.07% H: 3.08% C: 2.41%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 28.22% | O: 0.04% H: 3.14% C: 2.68%
drug global opioid report market

---

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
Published: 2021-01-11 (Crawled : 17:00) - biospace.com/
BMY | $48.56 0.54% 1.8M |

Health Technology

| -22.71% | O: 1.46% H: 2.91% C: 2.48%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 34.22% | O: -0.55% H: 1.0% C: -0.04%
AMGN | $265.32 0.98% 550K |

Health Technology

| 11.09% | O: 0.63% H: 0.15% C: -1.01%
collaboration disease cancer announces collaboration

---

Global Microbiome Market Marching Towards the Mainstream
Published: 2021-08-24 (Crawled : 15:15) - prnewswire.com
ACM | $93.585 0.37% 110K |

Industrial Services

| 47.01% | O: -0.19% H: 2.87% C: 2.47%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 16.1% | O: -0.75% H: 0.36% C: 0.27%
market

---

Global Cancer Immunotherapy Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Published: 2022-04-06 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| -7.68% | O: 0.23% H: 0.0% C: 0.0%
SNYNF | News | $92.7 600K |

Health Technology

| -12.71% | O: 4.21% H: 0.0% C: -0.61%
AZNCF | $138.24 800 |

Health Technology

| -1.68% | O: 1.45% H: 0.46% C: 0.19%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 5.15% | O: 1.98% H: 0.0% C: -1.11%
NVS | $93.815 1.35% 410K |

Health Technology

| 2.68% | O: 0.39% H: 0.53% C: 0.44%
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| -19.16% | O: 1.15% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -11.99% | O: 1.01% H: 0.0% C: 0.0%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 145.48% | O: -0.27% H: 2.95% C: 1.12%
BMY | $48.56 0.54% 1.8M |

Health Technology

| -35.89% | O: 0.05% H: 2.52% C: 2.49%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -14.65% | O: 1.74% H: 0.0% C: 0.0%
AZN | $68.545 0.27% 1.2M |

Health Technology

| -1.17% | O: 0.35% H: 2.64% C: 2.45%
AMGN | $265.32 0.98% 550K |

Health Technology

| 6.0% | O: -0.29% H: 1.42% C: 0.98%
immunotherapy cancer market

---

Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
Published: 2022-04-07 (Crawled : 02:00) - prnewswire.com
AZN | $68.545 0.27% 1.2M |

Health Technology

| -1.17% | O: 0.35% H: 2.64% C: 2.45%
cldn18 antibody license

---

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Published: 2024-02-08 (Crawled : 12:00) - prnewswire.com
AZNCF | $138.24 800 |

Health Technology

| 1.47% | O: -8.5% H: 2.46% C: 2.46%
IONS | $41.07 0.64% 140K |

Health Technology

| -17.62% | O: 0.2% H: 1.37% C: 0.68%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 2.58% | O: -6.81% H: 3.02% C: 2.42%
fda granted designation eplontersen

---

Gainers vs Losers

79%

21%

Top 10 Gainers

AGBA | News | $1.22 205.0% 86M |

Finance

EGOX | $0.0606 68.33% 250M |

NVFY | $3.45 63.51% 20M |

Consumer Durables

CHRO | $1.66 35.51% 70K |

n/a

INDO | $5.43 33.09% 10M |

Energy Minerals

ZCMD | $1.86 28.28% 29M |

Commercial Services

PAPL | $2.07 26.22% 550K |

RWOD | $10.08 26.05% 5.6M |

n/a

HUSA 4 | $2.07 23.95% 2.1M |

Energy Minerals

SRFM 4 | $0.6 21.29% 850K |

n/a

---

Your saved searches

---